Banyu Pharmaceutical Co. Ltd

Merck Sharp + Dohme Corp.

Msd K.k.

Mds K.k.

Hideki Kurihara

Lihu Yang

Jun Shibata

Norikazu Otake

Yoshio Ogino

Kenji Matsuda

Kazuhito Noguchi

Tomoshige Numazawa

Tadashi Shimamura

Masayuki Nakamura

Yoshikazu Iwasawa

Mitsuru Ohkubo

Morihiro Mitsuya

Kenji Niiyama

Nobuhiko Kawanishi

Tomoharu Iino

Takeru Yamakawa

Takeshi Sagara

Takashi Mita

Hiroshi Hirai

Sachie Arai

Tetsuya Sugimoto

Hideki Jona

Yoshiyuki Sato

Hitomi Watanabe

Hideya Komatani

Mikako Kawamura

Kaori Kamijo

Takashi Hashihayata

Yu Onozaki

Toshiaki Tsujino

Akiko Watanabe

Naohiro Tsukamoto

The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-a]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases. 

Spirochromanon derivatives

The present invention relates to a compound represented by the Formula [I]: Wherein:

Fused imidazole derivative

The present invention relates to a compound represented by Formula [I]: wherein

Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton

This invention relates to compounds which exhibit selective muscarinic Mreceptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I);  [in which A signifies a group expressed by a formula (a) or (b); Ar signifies optionally substituted aryl or heteroaryl; Band Bsignify aliphatic hydrocarbon; Rsignifies fluorine-substituted cycloalkyl; R, Rand Rsignify lower alkyl, single bond or alkylene bonded to B, or Rand Rare united to signify alkylene; Rand Rsignify hydrogen, lower alkyl, or a single bond or alkylene bonded to B; Rsignifies hydrogen, lower alkyl or a group expressed as &#x2014;N(R)R; and Xsignifies an anion].

Ester derivatives

This invention relates to compounds which exhibit selective muscarinic Mreceptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I);  Ar signifies optionally substituted aryl or heteroaryl; Band Bsignify aliphatic hydrocarbon; Rsignifies fluorine-substituted cycloalkyl; R, Rand Rsignify lower alkyl, single bond or alkylene bonded to B, or Rand Rare united to signify alkylene; Rand Rsignify hydrogen, lower alkyl, or a single bond or alkylene bonded to B; Rsignifies hydrogen, lower alkyl or a group expressed as &#x2014;N(R)R; and Xsignifies an anion].

The invention relates to isoxazolopyridone derivatives of a formula (I-a): wherein Rrepresents an optionally-substituted heteroaryl or phenyl group, Rrepresents an optionally-substituted phenyl or heteroaryl group, and Rrepresents a methyl group, provided that, (1) when Ris an unsubstituted phenyl group, then Rmust not be a para-substituted phenyl group of which the substituent is any of a methoxy group, a chloro group, a methyl group, a trifluoromethyl group, a fluoro group, a bromomethyl group or a dimethylaminomethyl group, and Rmust not be an unsubstituted heteroaryl group, and (2) when Ris a 4-tolyl group or a 4-fluorophenyl group, then Rmust not be an unsubstituted phenyl group, a 4-methoxyphenyl group or a 4-fluorophenyl group, or their pharmaceutically-acceptable salts. The isoxazolopyridone derivatives or their pharmaceutically-acceptable salts of the invention have a metabotropic glutamic acid receptor-antagonistic effect, and are useful for remedy of, for example, anxiety disorders, psychosomatic disorders, obsessive-compulsive neurosis, bipolar disorders, melancholia, eating disorders, schizophrenia, multi-infarct dementia, Alzheimer disease, epilepsy, Parkinson disease, Huntington's chorea, pain or retrograde neurosis.

Isoxazolopyridone derivatives and their use

This invention relates to compounds which exhibit selective muscarinic Mreceptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I);

Growing community of inventors

Tsukuba, Japan

Hideki Kurihara